Login to Your Account

Clinic Roundup

Friday, July 29, 2011
Polaris Group, of San Diego, dosed the first patient in a pivotal Phase III trial evaluating ADI-PEG 20 (pegylated arginine deiminase) in patients with hepatocellular carcinoma, or primary liver cancer. The randomized, double-blind, placebo-controlled, global study will enroll more than 600 patients who have failed prior systemic therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription